Sharma N, Anders H J, Gaikwadd A B. Fiend and friend in the renin angiotensin system: an insight on acute kidney injury [J]. Biomed Pharmacother, 2019, 110: 764-774.
[2]
Susantitaphong P, Cruz D N, Cerda J, et al. World incidence of AKI: a meta-analysis [J]. Clin J Am Soc Nephrol, 2013, 8(9): 1482-1493.
[3]
Ostermamn M, Liu K. Pathophysiology of AKI [J]. Best Pract Res Clin Anaesthesiol, 2017, 31(3): 305-314.
[4]
Khreba N A, Abdelsalam M, Wahab A M, et al. Kidney injury molecule 1 (KIM-1) as an early predictor for acute kidney injury in post-cardiopulmonary bypass (CPB) in open heart surgery patients [J]. Int J Nephrol, 2019, 2019: 6265307.
[5]
Hobson C, Ruchi R, Bihorac A. Perioperative acute kidney injury: risk factors and predictive strategies [J]. Crit Care Clin, 2017, 33(2): 379-396.
[6]
Ba Aqeel S H, Sanchez A, Batlle D. Angiotensinogen as a biomarker of acute kidney injury [J]. Clin Kidney J, 2017, 10(6): 759-768.
[7]
Dudoignon E, Moreno N, Deniau B, et al. Activation of the renin-angiotensin-aldosterone system is associated with acute kidney injury in COVID-19 [J]. Anaesth Crit Care Pain Med, 2020, 39(4): 453-455.
[8]
Cheungpasitporn W, Thongprayoon C, Srivali N, et al. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis [J]. Nephrol Dial Transplant, 2015, 30(6): 978-988.
[9]
Hsu C Y, Liu K D, Yang J, et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI [J]. Clin J Am Soc Nephro, 2020, 15(1): 26-34.
[10]
IwaI M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis [J]. Hypertens Res, 2009, 32(7): 533-536.
Kobori H, Nangaku M, Navar L G, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease [J]. Pharmacol Rev, 2007, 59(3): 251-287.
[13]
van den Heuvel M, Batenburg W W, Jainandunsing S, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney [J]. J Hypertens, 2011, 29(11): 2147-2155.
[14]
Kuai Y, Huang H, Dai X, et al. In PICU acute kidney injury stage 3 or mortality is associated with early excretion of urinary renin [J]. Pediatr Res, 2022, 91(5): 1149-1155.
[15]
Stanski N L, Pode Shakked N, Zhang B, et al. Serum renin and prorenin concentrations predict severe persistent acute kidney injury and mortality in pediatric septic shock [J]. Pediatr Nephrol, 2023, 38(9): 3099-3108.
[16]
Küllmar M, Saadat-gilani K, Weiss R, et al. Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients [J]. Am J Respir Crit Care Med, 2021, 203(9): 1119-1126.
[17]
Flannery A H, Ortiz-soriano V, Li X, et al. Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study [J]. Crit Care, 2021, 25(1): 294.
[18]
Sun C Y, Cherng W J, Jian H Z, et al. Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury-beyond the direct renin inhibition [J]. Hypertens Res, 2012, 35(3): 304-311.
[19]
Sparks M A, Crowley S D, Gurley S B, et al. Classical renin-angiotensin system in kidney physiology [J]. Compr Physiol, 2014, 4(3): 1201-1228.
Dou Y, Song D, Wang C, et al. The role of urinary angiotensinogen in kidney interstitial inflammation and renal prognosis [J]. Iran J Kidney Dis, 2019, 13(6): 372-379.
[22]
Chen C, Yang X, Lei Y, et al. Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome [J]. Clin J Am Soc Nephrol, 2016, 11(9): 1536-1544.
[23]
Yang X, Chen C, Tian J, et al. Urinary angiotensinogen level predicts AKI in acute decompensated heart failure: a prospective, two-stage study [J]. J Am Soc Nephrol, 2015, 26(8): 2032-2041.
[24]
Cui S, Wu L, Feng X, et al. Urinary angiotensinogen predicts progressive chronic kidney disease after an episode of experimental acute kidney injury [J]. Clin Sci (Lond), 2018, 132(19): 2121-2133.
[25]
Alge J L, Karakala N, Neely B A, et al. Urinary angiotensinogen and risk of severe AKI [J]. Clin J Am Soc Nephrol, 2013, 8(2): 184-193.
[26]
Alge J L, Karakala N, Neely B A, et al. Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit [J]. Crit Care, 2013, 17(2): R69.
[27]
Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption [J]. Clin Chem Lab Med, 2017, 55(8): 1074-1089.
[28]
Kobori H, Prieto-carrasquero M, Ozawa Y, et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin Ⅱ-dependent hypertension [J]. Hypertension, 2004, 43(5): 1126-1132.
[29]
Zhu Y, Xu D, Deng F, et al. Angiotensin (1-7) attenuates sepsis-induced acute kidney injury by regulating the NF-kappaB pathway [J]. Front Pharmacol, 2021, 12: 601909.
[30]
Silva L S, Peruchetti D B, Silva-aguiar R P, et al. The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury [J]. PLoS One, 2018, 13(9): e0203836.
[31]
Benedetto U, Sciarretta S, Roscitano A, et al. Preoperative angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting [J]. Ann Thorac Surg, 2008, 86(4): 1160-1165.
[32]
Peng F, Su J, Lin J, et al. Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis [J]. J Cardiovasc Pharmacol, 2015, 65(3): 262-268.
[33]
Gayat E, Hollinger A, Cariou A, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury [J]. Intensive Care Med, 2018, 44(5): 598-605.
Nishiyama A, Kim-mitsuyama S. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system [J]. J Pharmacol Sci, 2010, 113(4): 289-291.
[36]
Blasi E R, Rocha R, Rudolph A E, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J]. Kidney Int, 2003, 63(5): 1791-1800.
[37]
Martín-fernández B, Rubio-navarro A, Cortegano I, et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats [J]. PLoS One, 2016, 11(1): e0145946.
[38]
Rafiq K, Hitomi H, Nakano D, et al. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney [J]. J Pharmacol Sci, 2011, 115(1): 1-7.
Abdel-hakeem E A, Abdel Hafez S M N, Kamel B A, et al. Angiotensin 1-7 mitigates rhabdomyolysis induced renal injury in rats via modulation of TLR-4/NF-kB/iNOS and Nrf-2/heme-oxygenase-1 signaling pathways [J]. Life Sci, 2022, 303: 120678.
2024, Vol. 35 
